Skip to main content
Figure 12 | BMC Cancer

Figure 12

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Figure 12

Expression of CSC markers and CA125 in mouse tumors generated from ip transplantation of control, paclitaxel, CYT387 and combination of paclitaxel and CYT387-treated HEY cells. (A) Immunohistochemistry staining of tumor sections for the expression of Oct4, CD117 and CA125 was performed as described in Figure 11A. (B) Quantification of Oct4, CD117 and CA125 staining was obtained as described in Figure 11A. Significant variations between the groups are indicated by *P<0.05 and **P<0.01. Magnification 200×, scale bar = 10 μm. (C) The mRNA expression of EpCAM, CD44, CD117 and Oct4 in control, paclitaxel, CYT387 and paclitaxel plus CYT387-treated HEY cells-derived xenografts was performed by q-PCR as described in the Methods section. The resultant mRNA levels were normalised to 18S mRNA. The experiments were performed using four independent samples in triplicate. Significant intergroup variations are indicated by *P <0.05, **P<0.01.

Back to article page